Drug Profile
Research programme: NASH therapeutics - Eli Lilly and Company/Terns Pharmaceuticals
Alternative Names: Non-alcoholic steatohepatitis therapeuticsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Terns Pharmaceuticals
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 30 Oct 2018 Terns Pharmaceuticals plans to initiate a clinical trial for Non-alcoholic steatohepatitis for TERN 201 in the first half of 2019 (PO)
- 04 Apr 2018 Terns Pharmaceuticals in-licenses from Eli Lilly and Company three small molecule therapeutic candidates for the potential treatment of Non-alcoholic steatohepatitis